研究在刺激干扰素基因 (STING) 激动剂对癌症免疫治疗的激动剂方面取得了进展
Wen-Rui Shen1, Xin-Ran Shi1, Yi-Bo He2
1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
干扰素基因刺激剂 (STING) 激动剂在癌症免疫治疗中表现有前途,但单独有效性有限. 组合疗法,特别是免疫检查点封锁,是提高其抗瘤潜力的关键.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 干扰素基因 (STING) 途径的循环GMP-AMP合成酶 (cGAS) 刺激器是癌症免疫治疗的新目标.
- 刺痛激动剂是研究热点,各种类型表明临床前和临床前的承诺.
研究的目的:
- 审查癌症免疫治疗中STING激动剂的研究进展.
- 分析STING激动剂单一治疗的局限性,并总结组合疗法研究.
主要方法:
- STING激动剂的分类 (基于CDN的,非基于CDN的,基于金属的,间接的).
- 专注于各种激动剂类型的临床和临床前研究.
- 分析组合策略,特别是免疫检查点封锁 (ICB).
主要成果:
- 刺激通路的激活对于抗瘤免疫是至关重要的.
- 刺痛激动剂显示出显著的潜力,但在单一治疗中存在局限性.
- 组合疗法,特别是ICB,预计将增强治疗效果.
结论:
- 刺痛激动剂在癌症治疗中具有广泛的前景.
- 用STING激动剂单一治疗是有限的;组合疗法对于提高疗效至关重要.
- 将STING激动剂与ICB治疗结合起来是一个有前途的策略,可以提高癌症治疗结果.
更多相关视频
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
相关概念视频
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
